CNNMoney.com
Companies Economy International Corrections Pre-market Trading After-hours Trading Winners/Losers/Actives Bonds Currencies Commodities World Markets Money Magazine Real Estate Taxes Jobs Ask the Expert Money 101 Autos Mutual Funds The Help Desk Loan Center Best Places to Live Ask the Expert Ultimate Guide to Retirement Retirement Calculators Rules of Retirement Best Funds Best Places to Retire Fortune Brainstorm Tech Apple 2.0 Blog Big Tech Blog Sectors and Stocks Tech Talk Resource Guide Small Business Makeovers Questions & Answers Small Business Video 100 Best Places to Launch FSB 100 Fortune Small Business Fortune 500 Brainstorm Tech Investing Management C-Suite Rankings Main Create Portfolio Edit Portfolio Create Alerts Edit Alerts

Zicam may damage sense of smell - FDA

Shares of manufacturer Matrixx Initiatives plummet more than 55% after government warns consumers to discontinue use. Stock is halted.

EMAIL  |   PRINT  |   SHARE  |   RSS
 
google my aol my msn my yahoo! netvibes
Paste this link into your favorite RSS desktop reader
See all CNNMoney.com RSS FEEDS (close)
By Julianne Pepitone, CNNMoney.com contributing writer

matrixx_weekly.mkw.gif
When will the government come up with a plan to reform health care?
  • By the end of the year
  • By the end of Obama's term
  • It won't happen

NEW YORK (CNNMoney.com) -- Consumers should discontinue use of Zicam Cold Remedy nasal gel and related products because they can can permanently damage users' sense of smell, the government said Tuesday.

In a press release, the U.S. Food and Drug Administration advised consumers to stop use of three over-the-counter Zicam Cold Remedy products: nasal gel, nasal swabs and the discontinued "kids size" swabs.

The FDA warned the three products could cause anosmia, the loss of sense of smell, which "may be long-lasting or permanent."

After that news was released, shares of Scottsdale, Ariz.-based Zicam manufacturer Matrixx Initiatives Inc. (MTXX) plummeted 55.5% to $8.56 before trading was halted.

About 130 consumers since 1999 have reported a loss of smell after using Zicam products. Many said the condition occurred after their first dose, the FDA said. The agency advised anyone who has experienced problems after using Zicam products to contact a doctor.

Matrixx responds

The products named comprised about 40% of the company's net sales in 2009, according to a press release from Matrixx, which added that the company believes the Zicam products are safe and do not cause loss of smell.

Matrixx said the FDA's actions are "unwarranted" -- but the company is reviewing its options, which may include removing these products from the market.

A separate note on Matrixx's Web site zicamlawsuits.com, titled "Response to Those Who Are Concerned About Zicam's Purported Connection to Anosmia," says the products are safe and that "allegations to the contrary are scientifically unfounded and misleading."

However, the Matrixx note does acknowledge lawsuits that have been brought against the company, saying, "Although plaintiffs and their attorneys hoping for financial gain have sued Matrixx, no plaintiff has ever won a court case, because there is no known causal link."

Homeopathic drug regulations

Zicam is considered a "homeopathic remedy" rather than a drug. These types of products can be marketed without the government oversight required of "conventional" foods and drugs.

Manufacturers are not required to register their products with FDA, nor must they receive the FDA's approval before producing or selling these products.

The manufacturer is responsible for ensuring that the products are safe, and the FDA is responsible for taking action against any "unsafe" product after it reaches the market -- as it did with Zicam.

In its warning letter, the FDA said Matrixx was in violation of its regulations by failing to file a new drug application for the nasal gel and gel swabs, and that the products did not adequately warn of risks.

The agency sent Matrixx a warning letter saying these products can no longer be marketed without FDA approval, according to its press release. Matrixx has 15 business days to notify the FDA of specific steps taken to correct violations. To top of page

Features
Markets Last Change
Dow Jones 10,464.93 50.79 / 0.49%
Nasdaq 2,252.67 15.01 / 0.67%
S&P 500 1,118.02 3.97 / 0.36%
10-year Bond 96 28/32 Yield: 3.75%
U.S.Dollar 1 euro = $1.426 0.000
December 22, 2009 12:00 AM ET
CompanyPrice% Change
YRC Worldwide Inc 1.13 26.98%
UAL Corp 12.87 11.72%
American Intl Group Inc 31.34 11.69%
US Airways Group Inc 5.13 11.52%
Dec 22 3:53pm ET †
More Galleries
Obama's Main Street favorites President Obama meets often with small business owners, peppering his speeches with their stories. We checked in with 6 entrepreneurs touted by the President to find out how they handle health care. More
Meet the hardest working Santas This is no part-time gig for these St. Nicks. They've carved out a profession warming kids' hearts during the coldest time of year. More
An eyeblink glance at the economy Last quarter, the economy grew by the largest amount since the summer of 2007, but there are signs that things are still getting worse. More
Sponsors

© 2009 Cable News Network. A Time Warner Company. All Rights Reserved. Terms under which this service is provided to you. Privacy Policy. Advertising Practices.
Copyright © 2009 BigCharts.com Inc. All rights reserved. Please see our Terms of Use.
MarketWatch, the MarketWatch logo, and BigCharts are registered trademarks of MarketWatch, Inc.
Intraday data provided by Interactive Data Real-Time Services and subject to the Terms of Use.
Intraday data is at least 20-minutes delayed. All times are ET.
Historical, current end-of-day data, and splits data provided by Interactive Data Pricing and Reference Data.
Fundamental data provided by Morningstar, Inc..
SEC Filings data provided by Edgar Online Inc..
Earnings data provided by FactSet CallStreet, LLC.